Literature DB >> 17460444

Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma.

Hiroto Matsuse1, Hiroko Hirose, Tomoko Tsuchida, Susumu Fukahori, Chizu Fukushima, Yohei Mizuta, Shigeru Kohno.   

Abstract

BACKGROUND: Pulmonary dendritic cells (DCs) play critical roles in both allergy and in viral infection. Levels of cysteinyl leukotrienes (cysLTs) increase after allergen sensitization and viral infection and can modulate the migration and functions of DCs. The present study examines the effects of respiratory syncytial virus (RSV) infection on numbers of DCs and cysLT concentrations in lung tissues of mice sensitized with mite allergen.
METHODS: We examined Control, Dermatophagoides farinae allergen sensitized (Df), RSV infected (RSV) and Df allergen sensitized and RSV infected (Df-RSV) Balb/c mice. We then determined the number of CD11c-positive DCs and the LT concentration in lung tissues of the mice and examined lung pathology and cytokine profiles in thoracic lymph nodes.
RESULTS: Infection with RSV significantly enhanced allergic airway inflammation in Df mice with concomitant increases in Th1 and Th2 immunity. The number of DCs and the cysLT concentrations were significantly increased in the lungs of Df and RSV mice and more so in Df-RSV, than in Df mice.
CONCLUSIONS: The present findings suggest that RSV infection increases the number of DCs and the cysLT concentrations in lung tissues of asthma patients, both of which could result in enhanced allergic airway inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460444     DOI: 10.2332/allergolint.O-06-476

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  7 in total

1.  Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma.

Authors:  Takehiko Shibata; David M Habiel; Ana L Coelho; Steven L Kunkel; Nicholas W Lukacs; Cory M Hogaboam
Journal:  J Immunol       Date:  2014-03-21       Impact factor: 5.422

2.  Respiratory Syncytial Virus Nonstructural Protein 1 Promotes 5-Lipoxygenase via miR-19a-3p.

Authors:  Mei Zheng; Panpan Fan; Pu Yang; Junwen Zheng; Dongchi Zhao
Journal:  J Immunol Res       Date:  2022-05-20       Impact factor: 4.493

3.  A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye.

Authors:  Alla Musiyenko; Lucia Correa; Nicholas Stock; John H Hutchinson; Daniel S Lorrain; Gretchen Bain; Jilly F Evans; Sailen Barik
Journal:  Clin Vaccine Immunol       Date:  2009-09-16

4.  Effect of respiratory syncytial virus infection on regulated on activation, normal T-cells expressed and secreted production in a murine model of asthma.

Authors:  Yanghua Ju; Seung Jun Choi; Huisu Lee; Hyun Sook Kim; Sulmui Won; Yoon Hong Chun; Jong-Seo Yoon; Hyun Hee Kim; Joon Sung Lee
Journal:  Korean J Pediatr       Date:  2011-11-30

5.  Antiviral activity of ginseng extract against respiratory syncytial virus infection.

Authors:  Jong Seok Lee; Eun-Ju Ko; Hye Suk Hwang; Yu-Na Lee; Young-Man Kwon; Min-Chul Kim; Sang-Moo Kang
Journal:  Int J Mol Med       Date:  2014-04-22       Impact factor: 4.101

6.  The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID-19- related cough: A randomized, controlled clinical trial.

Authors:  Rasool Soltani; Sara Nasirharandi; Farzin Khorvash; Maryam Nasirian; Kian Dolatshahi; Atousa Hakamifard
Journal:  Clin Respir J       Date:  2022-07-31       Impact factor: 1.761

Review 7.  MicroRNAs: Mediators and Therapeutic Targets to Airway Hyper Reactivity After Respiratory Syncytial Virus Infection.

Authors:  Shuwen Feng; Dongxin Zeng; Junwen Zheng; Dongchi Zhao
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.